Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
Carlsmed, Inc. (CARL)
Company Research
Source: GlobeNewswire
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carlsmed’s aprevo® personalized interbody implants with revision data from a similar patient cohort receiving conventional stock implants. The comparator cohort was drawn from the multicenter dataset of the International Spine Study Group, which is comprised of senior spine surgeons dedicated to advancing the treatment of adult spinal deformity. Patients treated with aprevo® experienced significantly fewer revisions due to mechanical complications, showing a revision rate of 4.3% (n=
Show less
Read more
Impact Snapshot
Event Time:
CARL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARL alerts
High impacting Carlsmed, Inc. news events
Weekly update
A roundup of the hottest topics
CARL
News
- Carlsmed Reports Q4, FY 2025 revenue above estimate [Seeking Alpha]Seeking Alpha
- Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025GlobeNewswire
- Carlsmed (NASDAQ:CARL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Carlsmed (NASDAQ:CARL) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
CARL
Earnings
- 11/6/25 - Beat
CARL
Sec Filings
- 1/12/26 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- CARL's page on the SEC website